Axsome Therapeutics Revenue Surges 66%

Biopharmaceutical firm Axsome Therapeutics (NASDAQ:AXSM) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales hitting $118.8 million, surpassing analyst estimates of $118 million. However, its adjusted earnings per share (EPS) loss of $1.54 missed expectations of a $1 per share loss by a wide margin. The quarter was marked by strong sales from its commercial products, Auvelity and Sunosi, and heightened strategic investment in research and development (R&D) reflected in increased spending.Source: Axsome Therapeutics. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool